Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6171978 | 0.82 | PARP1 (0.36) | TP53HPGDTSHRGABRA1GABRB2 | |
| SCHEMBL6723346 | 0.73 | MAOA (0.36) | SMN1; SMN2LMNAKDM4EMITFPOLB | |
| SCHEMBL10382447 | 0.73 | SMN1; SMN2 (0.36) | SMN1; SMN2LMNAKDM4EMITFPOLB | |
| SCHEMBL22978617 | 0.70 | SMN1; SMN2 (0.34) | SMN1; SMN2LMNAKDM4EMITFPOLB | |
| SCHEMBL10192535 | 0.70 | MAOA (0.37) | SMN1; SMN2LMNAKDM4EMITFPOLB | |
| SCHEMBL1820342 | 0.68 | PTPN1 (0.36) | SMN1; SMN2LMNAKDM4EMITFPOLB | |
| SCHEMBL787684 | 0.68 | CREBBP (0.32) | SMN1; SMN2LMNAKDM4EMITFPOLB | |
| SCHEMBL8370012 | 0.66 | MGAM (0.47) | KDM4EHPGDMAOB | |
| SCHEMBL3310654 | 0.66 | MGAM (0.47) | KDM4EHPGDMAOB | |
| SCHEMBL28612909 | 0.65 | HPGD (0.54) | SMN1; SMN2HPGDTSHRGABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3297625-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAMAGE | Sulfateq B.V. (NL) | 2018-03-28 | — | — | EP | claimed |
| WO-2016188766-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAMAGE | SULFATEQ B.V. (NL) | 2016-12-01 | — | — | WO | claimed |
| US-20210227822-A1 | COMPOUNDS FOR PROTECTION OF CELLS | SULFATEQ B.V. (NL) | 2021-07-29 | — | — | US | disclosed |
| US-11006626-B2 | Compounds for protection of cells | SULFATEQ B.V. (NL) | 2021-05-18 | — | — | US | disclosed |
| US-20210024485-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAMAGE | SULFATEQ B.V. (NL) | 2021-01-28 | — | — | US | disclosed |
| US-10676452-B2 | Compound for the prophylaxis or treatment of organ damage | SULFATEQ B.V. (NL) | 2020-06-09 | — | — | US | disclosed |
| US-10426771-B2 | 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases | SULFATEQ B.V. (NL) | 2019-10-01 | — | — | US | disclosed |
| US-20190098890-A1 | COMPOUNDS FOR PROTECTION OF CELLS | SULFATEQ B.V. (NL) | 2019-04-04 | — | — | US | disclosed |
| US-10123529-B2 | Compounds for protection of cells | SULFATEQ B.V. (NL) | 2018-11-13 | — | — | US | disclosed |
| US-20180280384-A1 | 6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMAN-COMPOUNDS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE AIRWAY DISEASES | SULFATEQ B.V. (NL) | 2018-10-04 | — | — | US | disclosed |
| US-20180170892-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAGAMAGE | SULFATEQ B.V. (NL) | 2018-06-21 | — | — | US | disclosed |
| EP-3297625-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAMAGE | Sulfateq B.V. (NL) | 2018-03-28 | — | — | EP | disclosed |
| US-9913841-B2 | 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases | SULFATEQ B.V. (NL) | 2018-03-13 | — | — | US | disclosed |
| US-20170151234-A1 | 6-Hydroxy-2,5,7,8-Tetramethylchroman-Compounds for the Treatment of Chronic Obstructive Airway Diseases | SULFATEQ B.V. (NL) | 2017-06-01 | — | — | US | disclosed |
| WO-2016188766-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAMAGE | SULFATEQ B.V. (NL) | 2016-12-01 | — | — | WO | disclosed |
| US-20150342174-A1 | COMPOUNDS FOR PROTECTION OF CELLS | SULFATEQ B.V. (NL) | 2015-12-03 | — | — | US | disclosed |
| EP-2935232-A1 | COMPOUNDS FOR PROTECTION OF CELLS | Sulfateq B.V. (NL) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014098586-A1 | COMPOUNDS FOR PROTECTION OF CELLS | SULFATEQ B.V. (NL) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151234-A1 | 6-Hydroxy-2,5,7,8-Tetramethylchroman-Compounds for the Treatment of Chronic Obstructive Airway Diseases | HRH4, CFTR, HRH2 | DRD2 2065/4885SMN1; SMN2 2428/4885LMNA 2534/4885 |
| US-11006626-B2 | Compounds for protection of cells | CASP10, BAX, CASP9 | DRD2 1693/4885SMN1; SMN2 2348/4885LMNA 442/4885 |
| US-20190098890-A1 | COMPOUNDS FOR PROTECTION OF CELLS | CASP10, BAX, CASP9 | DRD2 1693/4885SMN1; SMN2 2348/4885LMNA 442/4885 |
| US-20180280384-A1 | 6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMAN-COMPOUNDS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE AIRWAY DISEASES | CFTR, HRH2, HRH4 | DRD2 1675/4885SMN1; SMN2 2789/4885LMNA 2641/4885 |
| US-20210227822-A1 | COMPOUNDS FOR PROTECTION OF CELLS | CASP10, BAX, CASP9 | DRD2 1693/4885SMN1; SMN2 2348/4885LMNA 442/4885 |
| US-10676452-B2 | Compound for the prophylaxis or treatment of organ damage | GLS, TXN2, SLC5A2 | DRD2 1736/4885SMN1; SMN2 3584/4885LMNA 1412/4885 |
| US-20210024485-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAMAGE | GLS, TXN2, SLC5A2 | DRD2 1736/4885SMN1; SMN2 3584/4885LMNA 1412/4885 |
| US-10426771-B2 | 6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive airway diseases | CFTR, HRH2, HRH4 | DRD2 1675/4885SMN1; SMN2 2789/4885LMNA 2641/4885 |
| US-10123529-B2 | Compounds for protection of cells | CASP10, BAX, CASP9 | DRD2 1693/4885SMN1; SMN2 2348/4885LMNA 442/4885 |
| US-20150342174-A1 | COMPOUNDS FOR PROTECTION OF CELLS | CASP10, BAX, CASP9 | DRD2 1693/4885SMN1; SMN2 2348/4885LMNA 442/4885 |
| US-20180170892-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAGAMAGE | LIPG, GLS, TXN2 | DRD2 1867/4885SMN1; SMN2 3274/4885LMNA 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.